The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ...